|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Peptide sequence around phosphorylation site of threonine 641 (E-L-T(p)-P-T) derived from Human PKC-beta|
|Storage buffer||PBS, pH 7.4, with 50% glycerol|
|Contains||0.02% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1:500-1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
A suggested positive control for Western blot is JK cells; suggested positive control for IHC is human lung carcinoma; suggested positive control for ICC/IF is MCF-7 cells.
Members of the Protein kinase C (PKC) family of serine/threonine protein kinases are grouped by their activation mechanism. Classical or conventional PKCs (PKC alpha-, betaI- , betaII- and gamma-) are activated by phosphatidylserine in a calcium dependent manner and can bind diacylglycerol. The Ca2+ insensitive novel PKCs (PKCs epsilon-, delta-, theta- and eta) are also activated by diacylglycerol and phosphatidylserine. The atypical PKCs (PKCs iota- and zeta-) are insensitive to Ca2+, DAG and phorbolesters. All PKCs isoforms consist of a highly conserved catalytic domain connected to a regulatory domain via a hinge region. PKCs are involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascades involving MAPK1/3 (ERK1/2) and RAP1GAP.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.